Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue

Dengue virus (DENV) threatens public health, especially in regions with tropical and subtropical climates. In 2024, the World Health Organisation reported 3.4 million confirmed dengue cases, with 16,000 severe cases and 3000 dengue-associated fatalities. The first licensed dengue vaccine, CYD-TDV (D...

Full description

Saved in:
Bibliographic Details
Main Authors: Brandon E. K. Tan, Seng Kong Tham, Chit Laa Poh
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Vaccines
Subjects:
dengue
live-attenuated vaccine
mutagenesis
attenuation
amino acid residue
antibody-dependent enhancement
Online Access:https://www.mdpi.com/2076-393X/13/5/532
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/5/532

Similar Items